Table 4.3.
Liposomal anticancer drugs in clinical phases
| Encapsulated drug | Trade name | Company | Indication | Clinical phase |
|---|---|---|---|---|
| Cisplatin | SPI-077 | Sequus | Advanced cancer | Ι/ΙΙ |
| Cisplatin | Lipoplatin | Regulon | Lung cancer | ΙΙΙ |
| Oxaliplatin | Aroplatin | Antigenics | Rectal cancer | ΙΙ |
| Vincristine | Marqibo | Inex/Enzon | Non-Hodgkin’s lymphomas, acute lymphatic leukemia, Hodgkin’s lymphomas (phase II/III) metastatic malignant uveal melanoma (phase III) | ΙΙ/ΙΙΙ |
| Lurtotecan | OSI0211 | OSI | Ovarian cancer, microcellular lung cancer | ΙΙΙ |
| Irinotecan metabolite | SN-38 | NeoPharm | Rectal and lung cancer | I/II |
| Topotecan | INX-0076 | Inex | Advanced cancer | I/II |
| Paclitaxel | LEP ETU | NeoPharm | Breast, ovarian, and lung cancer | I/II |
| Doxorubicin | ThermoDox | Celsion Corporation, Lawrenceville, NJ | Non-resectable hepatocellular carcinoma | III |
| Binolerbin | NX-0125 | Inex | Advanced cancer | Ι |